ArticleHuman genomics2018
Tensions in ethics and policy created by National Precision Medicine Programs.
Article in Human genomics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- The ethical aspects of human organ-on-chip models: A mapping review.Stem cell reports · 2025Review
- Precision oncology: transforming cancer care through personalized medicine.Medical oncology (Northwood, London, England) · 2025Review
- Understanding individualised genetic interventions as research-treatment hybrids.Journal of medical ethics · 2025Article
- The interplay of ethics and genetic technologies in balancing the social valuation of the human genome in UNESCO declarations.European journal of human genetics : EJHG · 2024Article
- Public values and guiding principles for implementing epitope compatibility in kidney transplantation allocation criteria: results from a Canadian online public deliberation.BMC public health · 2023Article
- Combating hypertension beyond genome-wide association studies: Microbiome and artificial intelligence as opportunities for precision medicine.Cambridge prisms. Precision medicine · 2023Review
- A conceptual analysis of public opinion regarding genome research in Japan.Frontiers in genetics · 2023Article
- Plastic diagnostics: The remaking of disease and evidence in personalized medicine.Social science & medicine (1982) · 2022Article
- Examining key factors impact on health science students' intentions to adopt genetic and pharmacogenomics testing: a comparative path analysis in two different healthcare settings.Human genomics · 2022Article
- Half of germline pathogenic and likely pathogenic variants found on panel tests do not fulfil NHS testing criteria.Scientific reports · 2022Article
- Perceptions of 'Precision' and 'Personalised' Medicine in Singapore and Associated Ethical Issues.Asian bioethics review · 2021Article
- Is There a Place for Responsible Artificial Intelligence in Pandemics? A Tale of Two Countries.Information systems frontiers : a journal of research and innovation · 2021Article
- Genomics of hypertension: the road to precision medicine.Nature reviews. Cardiology · 2021Review
- Attitudes of Costa Rican individuals towards donation of personal genetic data for research.Personalized medicine · 2021Article
- Disclosure of secondary findings in exome sequencing of 2480 Japanese cancer patients.Human genetics · 2021Article
- Governing Personalized Health: A Scoping Review.Frontiers in genetics · 2021Article
- Genomics of Blood Pressure and Hypertension: Extending the Mosaic Theory Toward Stratification.The Canadian journal of cardiology · 2020Review
- Ethics and Collateral Findings in Pragmatic Clinical Trials.The American journal of bioethics : AJOB · 2020Article
- Genetic testing, insurance discrimination and medical research: what the United States can learn from peer countries.Nature medicine · 2019Review
- Estimating carrier frequencies of newborn screening disorders using a whole-genome reference panel of 3552 Japanese individuals.Human genetics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Precision medicine promises to use genomics and other data-intensive approaches to improve diagnosis and develop new treatments for major diseases, but also raises a range of ethical and governance challenges. Implementation of precision medicine in "real world" healthcare systems blurs the boundary between research and care. This has implications for the meaning and validity of consent, and increased potential for discrimination, among other challenges. Increased sharing of personal information raises concerns about privacy, commercialization, and public trust. This paper considers national precision medicine schemes from the USA, the UK, and Japan, comparing how these challenges manifest in each national context and examining the range of approaches deployed to mitigate the potential undesirable social consequences. There is rarely a "one size" fits all solution to these complex problems, but the most viable approaches are those which take account of cultural preferences and attitudes, available resources, and the wider political landscape in which national healthcare systems are embedded.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.